Hemogenyx Pharmaceuticals PLC Announces Half-year Report

Hemogenyx Pharmaceuticals Plc

(“HEMO” or “the Company”)

Half-year Report

Interim Results for the period ended 30 June 2018

LONDON / ACCESSWIRE / September 28, 2018 / Hemogenyx Pharmaceuticals plc (LSE: HEMO), the Standard Listed biopharmaceutical group developing new therapies and treatments designed to transform bone marrow transplantation for the treatment of blood diseases, announces unaudited interim results for the six-month period ended 30 June 2018.

All financial amounts are stated in GBP British pounds unless otherwise indicated.

Key highlights

CDX Antibodies

· Continued progress towards the goal of submitting an IND application to the FDA for CDX antibodies

· First data results show CDX antibodies can attack and eliminate Acute Myelogenous Leukemia in vitro

· Development agreement with Global pharmaceutical company for CDX antibodies

Humanised mice

· Patent application filed for new type of humanised mouse with chimeric mouse-human blood system

· Rockefeller University Research Collaboration targeting new treatments for Lupus using humanised mice

· Collaboration with major US biotechnology firm worth up to US$250,000

Board & SAB appointments

· Appointment of Sir Marc Feldmann, pioneer of anti-TNF therapy, as Executive Chairman

· Appointment of cancer research expert Dr Michael Shepard, inventor of Herceptin, major breast cancer drug to Scientific Advisory Board

Commenting on Outlook, Sir Marc Feldmann, Executive Chairman, said:

“Overall the Board is very pleased with the progress being made, in particular the unlocking of opportunities for CDX antibodies, as well as the potential value that can be created through the Company’s new type of humanised mice. Hemogenyx is confident that these humanised mice will be of interest to large biopharmaceutical companies and has the potential to form the basis of significant future collaborations and the Company hopes to update shareholders on progress in this area.

“The Board believes that the Company is well-advanced on the planned development steps that were announced at Admission and we hope to provide further updates to shareholders as we progress. The Company looks forward to the future with confidence.”

Hemogenyx Pharmaceuticals Limited

www.hemogenyx.com

Dr Vladislav Sandler, Chief Executive Officer & Co-Founder

Via Walbrook PR

Sir Marc Feldmann, Executive Chairman

Northland Capital Partners Limited

Tel: +44 (0)20 3861 6625

Matthew Johnson, Vadim Alexandre, Dugald J Carlean

Peterhouse Corporate Finance Limited

Tel: +44 (0)20 7469 0930

Lucy Williams, Duncan Vasey

Walbrook PR (UK Media & Investor Relations)

Tel: +44 (0)20 7933 8780 or hemogenyx@walbrookpr.com

Paul McManus

Mob: +44 (0)7980 541 893

US Media enquiries

Lowell Goodman

Tel: +1 (323) 646-3249 or lowell@corbomitecomms.com

Please click on, or paste the following link into your web browser to view the full announcement;

http://www.rns-pdf.londonstockexchange.com/rns/2530C_1-2018-9-27.pdf

Source: Hemogenyx Pharmaceuticals plc

ReleaseID: 513006